NeuroMetrix (NURO) keeps making progress, yet Wall Street is not convinced the company has a future. Headline seen this morning (02016.01.21) prior to the market opening:
"NeuroMetrix, Inc. (Nasdaq: NURO) today reported regulatory approval in China for DPNCheck®, a diagnostic test for peripheral neuropathy. The press release said, "China is dealing with an epidemic of diabetes."
One week ago the company reported the following: "NeuroMetrix Announces Highly Positive Industry and Media Reaction to Quell® Wearable Pain Relief Technology at the 2016 Consumer Electronics Show."
NURO closed yesterday at $1.62. 52-week range: $1.35 - $7.84.
No comments:
Post a Comment